Impact of carfilzomib-based desensitization on heart transplantation of sensitized candidates.

[1]  G. Serban,et al.  Desensitizing highly sensitized heart transplant candidates with the combination of belatacept and proteasome inhibition , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  David A Hildeman,et al.  A prospective, iterative, adaptive trial of carfilzomib‐based desensitization , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  E. Albers,et al.  Management of the sensitized pediatric heart transplant patient. , 2019, Translational pediatrics.

[4]  J. Kobashigawa,et al.  Sensitization in Heart Transplantation: Emerging Knowledge: A Scientific Statement From the American Heart Association. , 2019, Circulation.

[5]  J. Friedewald,et al.  Prognostic tools to assess candidacy for and efficacy of antibody‐removal therapy , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  J. Kobashigawa,et al.  Crossing low-level donor-specific antibodies in heart transplantation. , 2019, Current opinion in organ transplantation.

[7]  L. Potena,et al.  The management of antibodies in heart transplantation: An ISHLT consensus document. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  J. Moreb,et al.  Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis , 2018, Leukemia & lymphoma.

[9]  J. Laubach,et al.  The proteasome and proteasome inhibitors in multiple myeloma , 2017, Cancer and Metastasis Reviews.

[10]  Byron H. Smith,et al.  32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody , 2017, Transplantation.

[11]  S. Yousem,et al.  Proteasome Inhibitor Carfilzomib‐Based Therapy for Antibody‐Mediated Rejection of the Pulmonary Allograft: Use and Short‐Term Findings , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  M. Dimopoulos,et al.  Cardiac and renal complications of carfilzomib in patients with multiple myeloma. , 2017, Blood advances.

[13]  J. Kobashigawa,et al.  Calculated panel-reactive antibody predicts outcomes on the heart transplant waiting list. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[14]  A. Israni,et al.  OPTN/SRTR 2015 Annual Data Report: Heart , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  A. Kfoury,et al.  Immunologic effects of continuous-flow left ventricular assist devices before and after heart transplant. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  J. Patel,et al.  Desensitization strategies in adult heart transplantation-Will persistence pay off? , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[17]  P S Heeger,et al.  Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation‐05 Study , 2016, American Journal of Transplantation.

[18]  H. Goldschmidt,et al.  Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. , 2016, The Lancet. Oncology.

[19]  J. Friedewald,et al.  Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  G. Bhat,et al.  Clinical outcomes in sensitized heart transplant patients bridged with ventricular assist devices , 2015, Clinical transplantation.

[21]  E. Reed,et al.  Reduced HLA Class II antibody response to proteasome inhibition in heart transplantation. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[22]  Aspire Investigators,et al.  Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma , 2015 .

[23]  R. Alloway,et al.  Prospective Iterative Trial of Proteasome Inhibitor‐Based Desensitization , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  R. Montgomery,et al.  Differential Effect of Bortezomib on HLA Class I and Class II Antibody , 2014, Transplantation.

[25]  X. Jouven,et al.  Complement-binding anti-HLA antibodies and kidney-allograft survival. , 2013, The New England journal of medicine.

[26]  W. Kremers,et al.  LVAD Implant as a Bridge to Heart Transplantation Is Associated with Allosensitization as Measured by Single Antigen Bead Assay , 2013, Transplantation.

[27]  D. Monos,et al.  Persistence of anti-human leukocyte antibodies in congenital heart disease late after surgery using allografts and whole blood. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[28]  J. Lunz,et al.  Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[29]  V. Sharma,et al.  Changes in IgG subclasses of donor specific anti-HLA antibodies following bortezomib-based therapy for antibody mediated rejection. , 2012, Clinical transplants.

[30]  E. Reed,et al.  Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[31]  G. Berry,et al.  Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[32]  E. Reed,et al.  The long‐term outcome of treated sensitized patients who undergo heart transplantation , 2011, Clinical transplantation.

[33]  Ronny Gustafsson,et al.  Desensitization and Heart Transplantation of a Patient With High Levels of Donor-Reactive Anti-Human Leukocyte Antigen Antibodies , 2010, Transplantation.

[34]  N. Pallet,et al.  Bortezomib as the Sole Post‐Renal Transplantation Desensitization Agent Does Not Decrease Donor‐Specific Anti‐HLA Antibodies , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[35]  M. Rose,et al.  Clinical relevance of complement-fixing antibodies in cardiac transplantation. , 2009, Human immunology.

[36]  S. Russell,et al.  Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. , 2007, The Annals of thoracic surgery.

[37]  M. Fishbein,et al.  Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[38]  M. Oz,et al.  Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. , 1999, Circulation.

[39]  L. Lambert,et al.  Prospective analysis of HLA immunogenicity of cryopreserved valved allografts used in pediatric heart surgery. , 1996, Circulation.